(0.61%) 5 159.26 points
(0.19%) 38 749 points
(0.69%) 16 268 points
(0.36%) $78.39
(4.67%) $2.24
(1.07%) $2 333.40
(3.57%) $27.64
(-0.02%) $965.15
(-0.08%) $0.928
(-0.42%) $10.83
(-0.17%) $0.796
(-0.13%) $91.33
0.61% $ 28.00
@ $28.73
Wydano: 8 bal. 2024 @ 16:34
Zwrot: -2.54%
Poprzedni sygnał: bal. 4 - 18:18
Poprzedni sygnał:
Zwrot: -1.44 %
Live Chart Being Loaded With Signals
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development...
Stats | |
---|---|
Dzisiejszy wolumen | 323 879 |
Średni wolumen | 1.70M |
Kapitalizacja rynkowa | 5.24B |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $-0.890 ) 2024-06-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.67 |
ATR14 | $0.0230 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Kumar Neil | Buy | 313 588 | Restricted Stock Units |
2024-03-12 | Kumar Neil | Buy | 45 140 | Stock Option (right to buy) |
2024-03-12 | Stephenson Brian C | Buy | 107 278 | Restricted Stock Units |
2024-03-12 | Stephenson Brian C | Buy | 15 442 | Stock Option (right to buy) |
2024-03-01 | Scott Randal W. | Sell | 2 500 | Common Stock |
INSIDER POWER |
---|
-18.12 |
Last 100 transactions |
Buy: 1 673 575 | Sell: 2 657 073 |
Wolumen Korelacja
BridgeBio Pharma Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ALTR | 0.941 |
RRGB | 0.928 |
ANSS | 0.928 |
SVC | 0.927 |
RCEL | 0.925 |
LPSN | 0.925 |
AUUD | 0.925 |
PLYA | 0.923 |
PDFS | 0.923 |
NARI | 0.921 |
10 Najbardziej negatywne korelacje | |
---|---|
NAKD | -0.928 |
GXII | -0.921 |
GSMG | -0.921 |
JUPW | -0.919 |
RAM | -0.915 |
PIXY | -0.913 |
AEAC | -0.913 |
CEG | -0.912 |
KINS | -0.911 |
SNGX | -0.911 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
BridgeBio Pharma Inc Korelacja - Waluta/Towar
BridgeBio Pharma Inc Finanse
Annual | 2023 |
Przychody: | $9.30M |
Zysk brutto: | $6.86M (73.71 %) |
EPS: | $-3.95 |
FY | 2023 |
Przychody: | $9.30M |
Zysk brutto: | $6.86M (73.71 %) |
EPS: | $-3.95 |
FY | 2022 |
Przychody: | $77.65M |
Zysk brutto: | $74.21M (95.58 %) |
EPS: | $-3.35 |
FY | 2021 |
Przychody: | $69.72M |
Zysk brutto: | $66.60M (95.53 %) |
EPS: | $-4.77 |
Financial Reports:
No articles found.
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej